AQST
NASDAQ · Pharmaceuticals
Aquestive Therapeutics Inc
$4.32
+0.09 (+2.13%)
Financial Highlights (FY 2026)
Revenue
53.26M
Net Income
-100,171,916
Gross Margin
58.3%
Profit Margin
-188.1%
Rev Growth
-2.2%
D/E Ratio
4.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 58.3% | 58.3% | 55.1% | 55.1% |
| Operating Margin | -159.5% | -143.6% | 28.0% | 27.5% |
| Profit Margin | -188.1% | -178.7% | 25.7% | 25.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 53.26M | 54.48M | 128.94M | 106.66M |
| Gross Profit | 31.08M | 31.79M | 71.02M | 58.74M |
| Operating Income | -84,943,765 | -78,201,092 | 36.05M | 29.37M |
| Net Income | -100,171,916 | -92,220,462 | 33.13M | 27.21M |
| Gross Margin | 58.3% | 58.3% | 55.1% | 55.1% |
| Operating Margin | -159.5% | -143.6% | 28.0% | 27.5% |
| Profit Margin | -188.1% | -178.7% | 25.7% | 25.5% |
| Rev Growth | -2.2% | -2.2% | +19.1% | -7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 221.21M | 221.21M | 204.59M | 185.15M |
| Total Equity | 47.24M | 47.24M | 356.51M | 373.84M |
| D/E Ratio | 4.68 | 4.68 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -91,146,728 | -88,573,436 | 53.66M | 42.58M |
| Free Cash Flow | — | — | 23.71M | 15.65M |